After a string of disappointing results, Novozymes ended the year on a strong footing with both Q4 and FY 16’s numbers coming slightly ahead of ours as well as consensus estimates. After a poor Q3 (sales contracted 4% and 3% on a reported and organic basis, respectively), sales rebounded 8% (6% organic and a 2% positive currency impact) to DKK3.7bn driven by surge across segments, except for Technical & Pharma (-17% reported basis and -12% organically). The outperformance was primar
23 Feb 2017
Changed sales pattern drives a solid Q4; end-markets uncertainties to persist
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Changed sales pattern drives a solid Q4; end-markets uncertainties to persist
Novonesis A/S (Novozymes A/S) Class B (NZYM:WBO) | 0 0 2.6% | Mkt Cap: 80,754m
- Published:
23 Feb 2017 -
Author:
Jyoti Prakash -
Pages:
4
After a string of disappointing results, Novozymes ended the year on a strong footing with both Q4 and FY 16’s numbers coming slightly ahead of ours as well as consensus estimates. After a poor Q3 (sales contracted 4% and 3% on a reported and organic basis, respectively), sales rebounded 8% (6% organic and a 2% positive currency impact) to DKK3.7bn driven by surge across segments, except for Technical & Pharma (-17% reported basis and -12% organically). The outperformance was primar